Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Orelabrutinib plus rituximab-based chemoimmunotherapy regimens in relapsed or refractory marginal zone lymphoma: A multicentric phase II trial

Shaohua Wu, Li Ma, Jingrong Wang, Xiaolian Wen, Meijing Zheng, Bing Xu, Hongling Ma, Yanli Wang, Liping Su

Blood (2025) 146 (Supplement 1): 7117.

https://doi.org/10.1182/blood-2025-7117

Published: 2025

Journal Articles

Renal response of selinexor, bortezomib, pomalidomide, and dexamethasone in newly diagnosed multiple myeloma patients with renal impairment: A phase 2, prospective, multicenter study

Blood (2025) 146 (Supplement 1): 5830.

https://doi.org/10.1182/blood-2025-5830

Published: 2025

Journal Articles

Mitoxantrone hydrochloride liposome (Lipo-MIT) combined with azacitidine and Chidamide can be an effective chemotherapy regimen for patients with angioimmunoblastic T-cell lymphoma (AITL)

Yanli Wang, Xuliang Shen, Guoxiang Zhang, Li Liang, Li Ma, Bing Xu, Jingrong Wang, Shaohua Wu, Min Bai, Xiaolian Wen, Le Li, Liping Su

Blood (2025) 146 (Supplement 1): 3652.

https://doi.org/10.1182/blood-2025-3652

Published: 2025

Journal Articles

Phase 2 study of aponermin +kt-decp in patients(pts) with Relapsed/Refractory multiple myeloma and extramedullary disease

Menghan Liu, Xiaoqi Qin, Weiwei Tian, Yuechen Zhang, Yanru Zhang, Lefu Huang, Wenjing Li, Jingrong Wang, Yanping Ma, Liping Su, Yan Yan, Aijun Liao, Wenming Chen, Aijun Liu

Blood (2025) 146 (Supplement 1): 2280.

https://doi.org/10.1182/blood-2025-2280

Published: 2025

Journal Articles

Mitoxantrone hydrochloride liposome (Lipo-MIT) combined with rituximab, gemcitabine, dexamethasone, and cisplatin (R-GDPM) in Relapsed/Refractory diffuse large B-cell lymphoma: A multicenter, single-arm study

Li Ma, Jin Zhao, Jingrong Wang, Bing Xu, Meijing Zheng, Junyuan Lang, Xiaolian Wen, Bin Yang, Shaohua Wu, Yanli Wang, Li Liang, Liping Su

Blood (2025) 146 (Supplement 1): 5476.

https://doi.org/10.1182/blood-2025-5476

Published: 2025

Journal Articles

Rituximab, cyclophosphamide, mitoxantrone hydrochloride liposome, vincristine, and prednisone (R-CMOP) in elderly patients with newly diagnosed diffuse large B-cell lymphoma: A multicenter, prospective study

Xiaolian Wen, Lieyang Wang, Li Ma, Bing Xu, Yanping Ma, Jingrong Wang, Shaohua Wu, Jin Zhao, Zhiqiang Zhao, Yalan Wang, Jie Liu, Liping Su

Blood (2025) 146 (Supplement 1): 3697.

https://doi.org/10.1182/blood-2025-3697

Published: 2025

Journal Articles

Mitoxantrone Hydrochloride Liposome (Lipo-MIT) Combined with Azacitidine and Chidamide Can be an Effective Chemotherapy Regimen for Patients with Angioimmunoblastic T-Cell Lymphoma (AITL)

Yanli Wang, Li Lang, Li Ma, Jingrong Wang, Shaohua Wu, Min Bai, Xuliang Shen, Xiaolian Wen, Le Li, Liping Su

Blood (2024) 144 (Supplement 1): 6514.

https://doi.org/10.1182/blood-2024-205043

Published: 2024

Journal Articles

Mitoxantrone Hydrochloride Liposome (Lipo-MIT) Combined with R-GDP Regimen in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Multicenter, Single-Arm Study

Li Ma, Jin Zhao, Jingrong Wang, Meijing Zheng, Xiaolian Wen, Junyuan Lang, Bin Yang, Liping Su

Blood (2024) 144 (Supplement 1): 6506.

https://doi.org/10.1182/blood-2024-205306

Published: 2024

Journal Articles

R-Cmop in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Multicenter, Prospective Study

Xiaolian Wen, Lieyang Wang, Li Ma, Jingrong Wang, Shaohua Wu, Zhiqiang Zhao, Yalan Wang, Liping Su

Blood (2024) 144 (Supplement 1): 6487.

https://doi.org/10.1182/blood-2024-207588

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Orelabrutinib plus rituximab-based chemoimmunotherapy regimens in relapsed or refractory marginal zone lymphoma: A multicentric phase II trial

Renal response of selinexor, bortezomib, pomalidomide, and dexamethasone in newly diagnosed multiple myeloma patients with renal impairment: A phase 2, prospective, multicenter study

Mitoxantrone hydrochloride liposome (Lipo-MIT) combined with azacitidine and Chidamide can be an effective chemotherapy regimen for patients with angioimmunoblastic T-cell lymphoma (AITL)

Phase 2 study of aponermin +kt-decp in patients(pts) with Relapsed/Refractory multiple myeloma and extramedullary disease

Mitoxantrone hydrochloride liposome (Lipo-MIT) combined with rituximab, gemcitabine, dexamethasone, and cisplatin (R-GDPM) in Relapsed/Refractory diffuse large B-cell lymphoma: A multicenter, single-arm study

Rituximab, cyclophosphamide, mitoxantrone hydrochloride liposome, vincristine, and prednisone (R-CMOP) in elderly patients with newly diagnosed diffuse large B-cell lymphoma: A multicenter, prospective study

Mitoxantrone Hydrochloride Liposome (Lipo-MIT) Combined with Azacitidine and Chidamide Can be an Effective Chemotherapy Regimen for Patients with Angioimmunoblastic T-Cell Lymphoma (AITL)

Mitoxantrone Hydrochloride Liposome (Lipo-MIT) Combined with R-GDP Regimen in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Multicenter, Single-Arm Study

R-Cmop in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Multicenter, Prospective Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only